PathMap Literature Based Discovery Engine
Share your Discovery:
Guaranteed to find unpublished literature based discoveries.
Neuroinflammatory astrocyte subtypes in the mouse brain
Pathologic Processes
_gates_from_pathologic_processes
Gene Expression Regulation
_gates_to_gene_expression_regulation
_gates_from_gene_expression_regulation
Biological Phenomena
_gates_to_biological_phenomena
_gates_from_biological_phenomena
Neuroinflammatory Diseases
_gates_to_neuroinflammatory_diseases
Hypothesis: If Botox were injected into the nerve ending on the third toe on the left foot, the toxin can "climb" retrograde from toe through motor neurons eventually to the brain and temporarily inhibit vesicular docking "from toe to head", potentially allowing a timed pharmacological therapeutic window for toxic EV clearance through the lymph system instead of docking and seeding.
Botulinum Toxins, Type A
_gates_from_botulinum_toxins__type_a
Axonal Transport
_gates_to_axonal_transport
_gates_from_axonal_transport
SNARE Proteins
_gates_to_snare_proteins
_gates_from_snare_proteins
Lymphatic Vessel Endothelial Hyaluronan Receptor-1
_gates_to_lymphatic_vessel_endothelial_hyaluronan_receptor_1
The ALS-T2D comorbidity is driven by a bidirectional, exosome-mediated proteostatic collapse. Peripheral tissues (muscle, pancreas) dictate CNS TDP-43 stability via exosomal miRNAs (miR-126a-5p) and glucose-dependent modifications (O-GlcNAcylation). Conversely, pharmacological activation of ubiquitin-peptidases (e.g., Acarbose targeting USP46) or restitution of glycolytic cofactors (F2,6BP) represent novel, cross-disciplinary therapeutic targets capable of halting systemic proteinopathy.
Diabetes Mellitus, Type 2
_gates_from_diabetes_mellitus__type_2
Extracellular Vesicles
_gates_to_extracellular_vesicles
_gates_from_extracellular_vesicles
DNA-Binding Proteins
_gates_to_dna_binding_proteins
_gates_from_dna_binding_proteins
Amyotrophic Lateral Sclerosis
_gates_to_amyotrophic_lateral_sclerosis
